Risks of inventory and fixed-asset valuation arising from changes in market size and market share
First written in FY2020. 5 of 7 entries say "Restated". Latest entry: FY2024.
0 other companies' latest entry also says "Restated".
- FY2024RestatedAnnual report
「If future trends in sales volumes used as these assumptions change, additional valuation losses may be recognized in the cost of sales of the pharmaceuticals segment for the following fiscal year and thereafter.」
The company continues to describe sales volume trends, slow-moving inventory, the potential for valuation and disposal losses, and the risk of fixed asset impairment due to changes in market size, market share and other factors. - FY2024-Q3RestatedAnnual report
「During the first three quarters of the current fiscal year, there were no new occurrences of the major risks that management recognises could materially affect the filing company's financial position, operating results or cash flows among the matters relating to business conditions, financial conditions and other matters described in the quarterly report, and no material changes to the "Business and Other Risks" described in the annual securities report for the previous fiscal year.」
The company states that there have been no significant changes to the risks of valuation losses and impairment losses due to fluctuations in market size, market share and sales volumes. - FY2024-Q1RestatedAnnual report
「There were no new major risks during the three months ended 30 June, and no material changes to the business and other risks described in the annual securities report for the previous fiscal year.」
The company states that there have been no significant changes to the risks of valuation losses and impairment losses due to fluctuations in market size, market share and sales volumes. - FY2023-Q3RestatedAnnual report
「During the first three quarters of the current fiscal year, there were no new occurrences of the major risks that management recognises could materially affect the filing company's financial position, operating results or cash flows among the matters relating to business conditions, financial conditions and other matters described in the quarterly report, and no material changes to the "Business and Other Risks" described in the annual securities report for the previous fiscal year.」
The company states that there have been no significant changes to the risks of valuation losses and impairment losses due to fluctuations in market size, market share and sales volumes. - FY2022RestatedAnnual report
「If future trends in sales volumes used as these assumptions change, additional valuation losses may be recognized in the cost of sales of the pharmaceuticals segment for the following fiscal year and thereafter.」
The company continues to describe sales volume trends, slow-moving inventory, and the potential for valuation and disposal losses as inventory valuation risks. It also describes the potential for fixed asset impairment due to changes in selling prices, market size, market share, discount rates and other factors. - FY2021Inventory valuation risk made more specificAnnual report
「The company’s inventory is valued by calculating, for each inventory item, the quantity expected to be discarded due to prolonged storage, setting the net realizable value of that quantity at zero to calculate the valuation loss, and then writing down the carrying amount based on declining profitability. If future trends in sales volumes used as these assumptions change, additional valuation losses may be recognized in the cost of sales of the pharmaceuticals segment for the following fiscal year and thereafter.」
The company has provided more detail on inventory valuation risk, including trends in market size, market share and sales volumes, slow-moving inventory, and the potential occurrence of valuation and disposal losses. - FY2020First statedAnnual report
「If future trends in the market size and market share used as these assumptions change, they may primarily affect the cost of pharmaceuticals sold in the financial statements for the following fiscal year and thereafter. Although the value-in-use calculations assess uncertainty after reflecting certain risks, changes in significant assumptions may result in impairment losses in the financial statements for the following fiscal year and thereafter.」
The company describes the potential impact on future cost of sales and impairment losses from changes in market size, market share, selling prices, discount rates and other assumptions underlying inventory valuation and fixed asset impairment.